ImmunityBio (IBRX) Earnings Analysis
ImmunityBio (IBRX) has no confirmed upcoming earnings date. Last quarter (2026-05-07) it missed with EPS -0.62 USD vs -0.08 USD est (-675%). It has beaten estimates in 2/5 recent quarters (40%). Trailing P/E -8.80.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does IBRX next report earnings?
No confirmed upcoming earnings date is currently scheduled for IBRX. This page updates as the calendar is published.
IBRX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | -0.62 USD | -0.08 USD | -675% | Miss |
| 2026-02-23 | -0.06 USD | -0.08 USD | +25% | Beat |
| 2025-05-12 | -0.15 USD | -0.12 USD | -25% | Miss |
| 2025-03-03 | -0.15 USD | -0.26 USD | +42.3% | Beat |
| 2024-08-12 | -0.2 USD | -0.17 USD | -17.6% | Miss |
Beat rate: 2/5 (40%) over reported quarters with consensus data.
IBRX valuation and analyst view
| Trailing P/E | -8.80 |
|---|---|
| Trailing EPS | -0.83217 USD |
| Price / book | -8.86 |
| Dividend yield | 0.00% |
| Market cap | 7.99B |
| Analyst consensus | Buy (5 buy / 0 hold / 0 sell) |
| Avg price target | 12 USD |
Related research pages
Frequently asked questions
When is ImmunityBio (IBRX)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for IBRX. This page updates as the calendar is published.
Did IBRX beat earnings last quarter?
In its 2026-05-07 report, IBRX posted EPS of -0.62 USD versus a -0.08 USD estimate — a miss of 675%.
What is IBRX's earnings track record?
Over the last 5 reported quarters with consensus data, IBRX beat estimates 2 times (40%).
What is IBRX's current P/E ratio and EPS?
IBRX trades at a trailing P/E of -8.80 on trailing EPS of -0.8321702565261171 USD.
What do analysts rate IBRX?
Analyst consensus is "Buy" across 5 ratings (0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 12 USD.